Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program
Last fall, Santhera Pharmaceuticals unceremoniously dumped a Duchenne program after it flunked a Phase III trial, forcing a wave of layoffs that trimmed the biotech’s staff from 120 to 40. Now, the Swiss company believes it’s found a path to a comeback with a different candidate in Duchenne.
Santhera revealed topline results from a Phase IIb study for its vamorolone program, saying two different doses each hit the primary endpoint compared with placebo. Tuesday’s data give the biotech confidence to potentially seek approval for both dosage levels with the aim of submitting an NDA in the first quarter of next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.